Chung-Han Lee
Overview
Explore the profile of Chung-Han Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
4158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ged Y, Touma A, Meza Contreras L, Elias R, Van Galen J, Cupo O, et al.
J Immunother
. 2025 Feb;
48(3):113-117.
PMID: 39901604
Metastatic translocation renal cell carcinomas (mtRCCs) are rare and aggressive tumors with limited treatment options. Recent studies demonstrated promising activity of immune-oncology (IO) combinations in mtRCC. However, the effectiveness of...
2.
Doshi S, Knezevic A, Gonzalez C, Fischer P, Goodman R, Gornell S, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102268.
PMID: 39616970
Purpose: Clinical trials enable renal cell carcinoma (RCC) patients to receive promising investigational agents, yet access may be limited. Telemedicine (TM) is an increasingly utilized platform that can expand access,...
3.
Tsai M, Lee C, Wu A, Lei Y, Chen H, Wu Y
Materials (Basel)
. 2024 Nov;
17(22).
PMID: 39597258
The geometry of implants plays a crucial role in the success of All-on-Four treatments for the lower jaw. This study builds upon prior research by evaluating the biomechanical performance of...
4.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 Oct;
87(1):96.
PMID: 39426859
No abstract available.
5.
Ma J, Del Balzo L, Walch H, Khaleel S, Knezevic A, Flynn J, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39107179
Background: Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements...
6.
Mantia C, Jegede O, Plimack E, Powles T, Motzer R, Tannir N, et al.
J Immunother Cancer
. 2024 Jul;
12(7.
PMID: 39060019
Background: Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation...
7.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 May;
86(2):90-94.
PMID: 38782695
Treatment options are limited for patients with non-clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib...
8.
Lee C, Shah A, Rao A, Taylor M, Di Simone C, Hsieh J, et al.
Eur Urol
. 2024 May;
86(5):470-473.
PMID: 38777648
No abstract available.
9.
Reese S, Eismann L, White C, Villada J, Khaleel S, Ostrovnaya I, et al.
Urol Oncol
. 2023 Dec;
42(2):32.e9-32.e16.
PMID: 38135627
Purpose: The use of systemic immune checkpoint blockade before surgery is increasing in patients with metastatic renal cell carcinoma, however, the safety and feasibility of performing consolidative cytoreductive nephrectomy after...
10.
Kotecha R, Doshi S, Knezevic A, Chaim J, Chen Y, Jacobi R, et al.
Eur Urol Oncol
. 2023 Nov;
7(4):804-811.
PMID: 37945488
Background: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient...